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Scheme 1. Key steps in synthesis of the precursor
The serotonin (5-HT) system, one of the most important 
neurotransmitter systems, has been classified into seven subtypes 
(5-HT1-7). Among these subfamilies, 5-HT1A receptors in the 
central nervous system are strongly implicated in psychiatric 
disorders such as depression, anxiety and schizophrenia.1,2 Thus 
molecular imaging agents for the 5-HT1A have been intensively 
studied since the past decade.3,4 Positron emission tomography 
(PET) as a non-invasive imaging technique with a high-sensi-
tivity (10‒9 ‒ 10‒12 M) and quantitative property, provides the 
means to visualize receptor densities in living system. 5,6 PET 
can play an important role both in assessing the neuropsychiatric 
disorders and in therapies with already developed pharma-
ceuticals.7,8,9
It is known that only high affinity agonists bind to receptors 
while antagonists’ binding is relatively insensitive to their affi-
nity.10,11 Thereby, a number of antagonist tracers have been 
developed as PET imaging agents on the basis of the WAY- 
100635 which is a selective antagonist for 5-HT1A receptors at 
both somatodendritic and postsynaptic receptor sites. 12-16 Struc-
tural analogues were designed to have stability to metabolism 
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Scheme 2. Synthesis of Mefway precursor. Reagents and conditions: i) choroacetyl chloride, TEA, CH2Cl2, rt, 79%, ii) 1-(2-methoxy-
phenyl)-piperazine, K2CO3, NaI, DMF, 80 oC, 84%, iii) LiAlH4, THF, rt, 76%, iv) oxalylchloride, trans-4-carbomethoxycyclohexane-1- 
carboxylic acid, CH2Cl2, rt, 83%, v) LiAlH4, Et2O, 0 oC, 57%, vi) Ts2O, TEA, CH2Cl2, rt, 75%.
with high affinity, and selectivity for the 5-HT1A. The most 
important drawback of these compounds is the significant de-
fluorination that causes low-quality images due to contamina-
tion of 18F-fluoride ion in the skull. Recently, Neil Saigal et al. 
reported [18F]Mefway ((N-2-{2-[4-(2-methoxyphenyl) piper-
azinyl]ethyl}-N-(2-pyridyl)-N-(4-18F-fluoro-methylcyclo-he-
xane) carboxamide) as a potent PET agent for 5-HT1A receptors. 
This compound had not only high target-to-non target ratios in 
receptor rich regions but also little defluorination.17
However, synthesis of its precursor, trans-N-{2-[4-(2-me-
thoxyphenyl)piperazinyl]ethyl}-N-(2-pyridyl)-N-(4-tosyloxy-
methylcyclohexane)carboxamide, prior to the fluorination was 
quite inefficient with the low overall yield for the development 
of radiopharmaceutical due to the significant breakdown of 
amide bond, i.e., up to 70% of starting substrate, during the re-
duction of carbomethoxy group toward WAY-100635 deriva-
tive. Thereby, an efficient synthesis of trans-[18F]Mefway pre-
cursor is needed which we would like to describe with adapta-
tion of acid chloride-assisted coupling reaction and an improved 
reduction method.
WAY-100634 (3) was prepared as previously described.8 Re-
action of 2-aminopyridine with chloroacetyl chloride at room 
temperature provided the 2-(chloroacetyl)amidopyridne (1) as 
a intermediate. The treatment of the intermediate with 1-(2- 
methoxyphenyl)piperzines in DMF at 80 oC in the presence of 
K2CO3 and NaI gave the corresponding N-2-[2-{4-(2-methoxy-
phenyl)-1-piperazinyl}ethyl]amidopyridine (2), which is sub-
sequently reduced to desired product 3, using LiAlH4 in THF 
at room temperature.
The WAY-100634 was coupled to trans-4-carbomethoxy-
cyclohexanecarbonyl chloride in dichloromethane in the pre-
sence of triethylamine at room temperature, yielding trans-N- 
2-{2-[4-(2-methoxy-phenyl)piperazinyl]ethyl}-N-(2-pyridyl)- 
N-(4-carboxymethylcyclohexane) carboxamide (4). In this 
reaction, we used oxalyl chloride as a coupling agent instead 
of benzotriazole-1-yloxytris-(dimethylamino)-phosphonium 
hexafluoro-phosphate (BOP) to enhance reactivity of carboxylic 
acid. This method improved the reaction yield up to 83% higher 
than previously reported method using BOP.17 Specific reduc-
tion of carbomethoxy group in 4 was conducted in LiAlH4 in 
Et2O at 0 oC to provide trans-N-2-{2-[4-(2-methoxyphenyl) 
piperazinyl]ethyl}-N-(2-pyridyl)-N-(4-hydroxymethylcyclo-
hexane)carbox-amide (5) in a 57% yield. This new procedure 
improves the reaction yield significantly compared to the pre-
vious protocol.17
The treatment of same substrate 5 with LiAlH4 in THF facili-
tated significant breakdown of the amide bond to yield com-
pound 3 in more than 60% yield due to the possible presence 
of adventitious water in THF or unusual reactivity of LiAlH4 in 
THF solution.17 For the preparation of the tosylated Mefway pre-
cursor 6, the hydroxyl compound 5 was reacted with p-toluene-
sulfonyl anhydride at room temperature in dichloromethane 
in the presence of triethylamine to afford the precursor of 
[18F]Mefway in 75% yield.
In conclusion, we developed an efficient synthetic pathway 
for the preparation of the precursor of [18F]Mefway, which 
consisted of the improved the acid chloride coupling reaction 
to activate carboxylic acid and proper reduction condition to 
suppress breakdown of amide bond.
Experimental Section
N-2-(2-Chloroethyl)amidopyridine (1). Chloroacetyl chlo-
ride (2.39 mL, 32.97 mmol) was slowly added to the mixture 
of 2-aminopyridine (1.88 g, 19.98 mmol) and TEA (4.30 mL, 
30.69 mmol) in dry dichlorometane (100 mL) at 0 oC. The 
reaction mixture was stirred at room temperature under an Ar 
atmosphere for 3 h. The organic layer was extracted with CH2Cl2, 
washed with water, and dried over anhydrous MgSO4. The 
residue was purified by flash column chromatography (3:1 
hexane/ethyl acetate) to give product (2.68 g, 79%) as a white 
solid. (Caution! VERY IRRITATIVE SOLID) 1H NMR (CDCl3, 
300 MHz) δ 4.20 (s, 2H), 7.09-7.14 (m, 1H), 7.77 (m, 1H), 
8.22-8.28 (m, 2H), 9.45 (s, 1H); 13C NMR (CDCl3, 75 MHz) 
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δ 42.8, 114.3, 120.5, 139.1, 147.1, 150.4, 164.7; HRMS (FAB+, 
m-nitrobenzylalcohol): Calcd for C7H8ON2Cl: 171.0325, Found: 
171.0324. 
N-2-[2-{4-(2-Methoxyphenyl)-1-piperazinyl}ethyl]amido-
pyridine (2). The mixture of 1-(2-methoxy)piperazine (0.20 
mL, 1.17 mmol) and K2CO3 (0.40 g, 2.93 mmol) in DMF (8 mL) 
was stirred at 80 oC for 1 h. After cooling down to room tem-
perature, a solution of compound (1) (0.20 g, 1.17 mmol) in 
DMF (2 mL) and sodium iodide (0.025 g, 0.17 mmol) were 
added to the mixture. The reaction mixture was stirred at 80 oC 
for 3 h, cooled to the room temperature. The organic layer was 
extracted with ethyl acetate, washed with water, and dried over 
anhydrous MgSO4. The residue was purified by flash column 
chromatography (50:1 CH2Cl2/MeOH to 20:1 CH2Cl2/MeOH) 
to give product (0.32 g, 84%) as pale yellow oil. 1H NMR 
(CDCl3, 300 MHz) 2.82-2.85 (m, 4H), 3.18 (s, 4H), 3.24 (s, 
2H), 3.87 (s, 3H), 6.86-7.06 (m, 5H), 7.69-7.75 (m, 1H), 8.25- 
8.33 (m, 2H), 9.64 (s, 1H); 13C NMR (CDCl3, 75 MHz) δ 50.6, 
53.8, 55.4, 62.3, 111.2, 113.9, 118.4, 119.9, 121.0, 123.2, 138.3, 
140.9, 148.0, 151.0, 152.3, 169.2; HRMS (FAB+, m-nitrobenzyl-
alcohol): Calcd for C18H23O2N4: 327.1821, Found: 327.1818.
N-2-[2-{4-(2-Methoxyphenyl)-1-piperazinyl}ethyl]-N-(2- 
pyridinyl)amine (3). 1 M LiAlH4/THF (6.70 mL, 6.70 mmol) 
was slowly added to a solution of compound (2) (0.73 g, 2.24 
mmol) in dry THF (10 mL) at 0 oC. The mixture was stirred at 
room temperature under an Ar atmosphere for 3 h. After quen-
ching with saturated aqueous NH4Cl at 0 oC for 30 min, the 
mixture was filtrated with ethyl acetate. The organic layer was 
extracted with ethyl acetate, washed with water, and dried over 
anhydrous MgSO4. The residue was purified by flash column 
chromatography (50:1 CH2Cl2/MeOH to 20:1 CH2Cl2/MeOH) 
to give product (0.53 g, 76%) as pale yellow oil. 1H NMR 
(CDCl3, 300 MHz) δ 2.68-2.72 (m, 6H), 3.10 (s, 4H), 3.36-3.41 
(m, 2H), 3.87 (s, 3H), 5.14 (s, 1H), 6.40-6.43 (d, 1H, J = 8.4 Hz), 
6.54-6.59 (m, 1H), 6.85-7.04 (m, 4H), 7.39-7.45 (m, 1H), 8.08- 
8.11 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 38.5, 50.7, 53.1, 
55.3, 56.8, 107.0, 111.1, 112.7, 118.2, 121.0, 122.9, 137.3, 
141.3, 148.2, 152.3, 158.8; HRMS (FAB+, m-nitrobenzylalco-
hol): Calcd for C18H25ON4: 313.2028, Found: 313.2030.
trans-N-2-{2-[4-(2-Methoxyphenyl)piperazinyl]ethyl}-N-
(2-pyridyl)-N-(4-carboxymethylcyclohexane)carboxamide 
(4). Oxalylchloride (0.19 mL, 2.13 mmol) was added to a solu-
tion of trans-4-carbomethoxycyclohexane-1-carboxylic acid 
(0.20 g, 1.05 mmol) in dry CH2Cl2 (10 mL), and the mixture 
was refluxed for 2 h. After removing solvent and unreacted 
oxalylchloride in vacuo, the product was re-dissolved in dry 
CH2Cl2. Compound (3) (0.22 g, 1.05 mmol) and TEA (0.16 mL, 
1.14 mmol) were added to the previous product at 0 oC. The 
reaction mixture was stirred at room temperature under an Ar 
atmosphere for 2 h. After the mixture was washed with 10% 
aqueous NaHCO3 (100 mL), the organic layer was extracted 
with CH2Cl2, and dried over anhydrous MgSO4. The residue 
was purified by flash column chromatography (ethyl acetate, 
0.1% v/v TEA) to give product (0.28 g, 83%) as pale yellow 
oil. 1H NMR (CDCl3, 300 MHz) δ 1.17-1.25 (m, 2H), 1.62-1.66 
(m, 2H), 1.84-1.96 (m, 4H), 2.25-2.29 (m, 2H), 2.58-2.63 (m, 
6H), 2.98 (s, 4H), 3.62 (s, 3H), 3.84 (s, 3H), 3.95-4.00 (m, 2H), 
6.83-7.00 (m, 4H), 7.24-7.31 (m, 2H), 7.74-7.80 (m, 1H), 8.51- 
8.53 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 27.8, 28.3, 41.3, 
42.1, 44.8, 50.1, 51.4, 53.0, 55.2, 55.6, 111.0, 117.9, 120.7, 
121.9, 122.4, 122.8, 138.2, 140.9, 149.2, 152.0, 175.5, 176.0; 
HRMS (FAB+, m-nitrobenzylalcohol): Calcd for C27H37O4N4: 
481.2815, Found: 481.2814.
trans-N-2-{2-[4-(2-Methoxyphenyl)piperazinyl]ethyl}-N-
(2-pyridyl)-N-(4-hydroxymethylcyclohexane)carboxamide 
(5). 1 M LiAlH4/diethyl ether (0.16 mL, 0.16 mmol) was slowly 
added to the solution of compound (4) (0.076 g, 0.16 mmol) in 
diethyl ether (5 mL) at 0 oC. The reaction mixture was stirred 
for 30 min at 0 oC under an Ar atmosphere, and quenched with 
saturated aqueous NH4Cl. The organic layer was extracted with 
ethyl ether, and then evaporated solvent under reduced pressure. 
The residue was purified by gravity column chromatography 
using neutral silica gel (30:1 CH2Cl2/MeOH) to give product 
(0.041 g , 57 % ) as colorless oil. 1H NMR (CDCl3, 300 MHz) 
δ 1.58-1.85 (m, 10H), 2.59-2.63 (m, 6H), 2.98 (s, 4H), 3.37-3.39 
(d, 2H, J = 6.0 Hz), 3.84 (s, 3H), 3.96-4.01 (t, 2H, J = 6.9 Hz), 
6.83-6.98 (m, 4H), 7.22-7.28 (m, 2H), 7.74-7.76 (m, 1H), 
8.51-8.53 (m, 1H); 13C NMR (CDCl3, 75 MHz) δ 28.4, 28.9, 
39.6, 42.3, 45.2, 50.6, 53.3, 55.3, 56.1, 68.3, 111.1, 118.1, 
120.9, 122.3, 122.8, 138.1, 141.3, 149.3, 152.2, 155.8, 176.0; 
HRMS (FAB+, m-nitrobenzylalcohol): Calcd for C26H37O3N4: 
453.2866, Found: 453.2870.
trans-N-2-{2-[4-(2-Methoxyphenyl)piperazinyl]ethyl}-N-
(2-pyridyl)-N-(4-tosyloxymethylcyclohexane)carboxamide 
(6). p-Toluenesulfonyl anhydride (0.018 g, 0.056 mmol) and 
TEA (0.0072 mL, 0.050 mmol) were added to the solution of 
compound (5) (0.021 g, 0.046 mmol) in CH2Cl2 (5 mL). The 
reaction mixture was stirred at room temperature under an Ar 
atmosphere for 48 h. After the mixture was washed with 10% 
aqueous NaHCO3 (100 mL), the organic layer was extracted 
with CH2Cl2, and dried over anhydrous MgSO4. The residue was 
purified by gravity column chromatography using neutral silica 
gel (20:1 CH2Cl2/MeOH) to give product (0.022 g, 75%) as 
colorless oil. 1H NMR (CDCl3, 300 MHz) δ 1.25-1.78 (m, 10H), 
2.44 (s, 3H), 2.57-2.61 (m, 6H), 2.97 (s, 4H), 3.74-3.76 (d, 2H), 
3.84 (s, 3H), 3.96-3.98 (d, 2H), 6.83-6.96 (m, 4H), 7.25-7.33 (m, 
4H), 7.72-7.77 (m, 3H), 8.51-8.53 (m, 1H); 13C NMR (CDCl3, 
75 MHz) δ 21.6, 28.0, 28.5, 36.4, 41.8, 45.3, 50.6, 53.4, 55.3, 
56.1, 74.9, 111.1, 118.1, 120.9, 122.2, 122.4, 122.8, 127.8, 
129.8, 132.9, 138.2, 141.3, 144.7, 149.3, 152.2, 155.8, 175.6; 
HRMS (FAB+, m-nitrobenzylalcohol): Calcd for C33H43O5N4S: 
607.2954, Found: 607.2954.
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